Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $7.50

Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of brokerages have issued reports on SANA. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 target price on the stock. Wedbush started coverage on Sana Biotechnology in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Saturday, September 27th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th.

Sana Biotechnology Stock Up 5.1%

NASDAQ SANA opened at $4.16 on Tuesday. The company has a market cap of $989.29 million, a PE ratio of -3.92 and a beta of 1.91. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $7.30. The firm’s 50-day simple moving average is $3.42 and its two-hundred day simple moving average is $2.81.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, equities research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SANA. Marex Group plc bought a new stake in Sana Biotechnology during the second quarter valued at $10,423,000. Corient Private Wealth LLC raised its stake in Sana Biotechnology by 264.7% in the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after purchasing an additional 824,505 shares in the last quarter. AQR Capital Management LLC lifted its position in Sana Biotechnology by 136.7% during the second quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company’s stock valued at $3,703,000 after purchasing an additional 783,217 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Sana Biotechnology in the 2nd quarter worth approximately $1,916,000. Finally, Millennium Management LLC increased its holdings in shares of Sana Biotechnology by 604.8% in the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company’s stock worth $1,188,000 after buying an additional 625,481 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.